AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575

Reuters

31 May

<a href="https://laohu8.com/S/ABCL">AbCellera Biologics</a> Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575

VANCOUVER, British Columbia-- AbCellera Biologics Inc. (Nasdaq: ABCL) has announced that it has received a No Objection Letter from Health Canada, granting authorization for its Clinical Trial Application for ABCL575. This investigational antibody medicine is being developed to treat moderate-to-severe atopic dermatitis and potentially other inflammatory and autoimmune conditions. ABCL575 is characterized as an Fc-silenced, half-life extended antibody targeting the OX40 ligand. The company plans to initiate a Phase 1 clinical trial in the third quarter of 2025, which will assess the safety and pharmacokinetics of the drug when administered subcutaneously in healthy participants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250530123396) on May 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2539271187"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539271187\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2539271187?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-31 01:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539271187","market":"nz","top_or_hot":-1,"title":"AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VANCOUVER, British Columbia-- AbCellera Biologics Inc. (Nasdaq: ABCL) has announced that it has received a No Objection Letter from Health Canada, granting authorization for its Clinical Trial Application for ABCL575. This investigational antibody medicine is being developed to treat moderate-to-severe atopic dermatitis and potentially other inflammatory and autoimmune conditions. ABCL575 is characterized as an Fc-silenced, half-life extended antibody targeting the OX40 ligand. The company plans to initiate a Phase 1 clinical trial in the third quarter of 2025, which will assess the safety and pharmacokinetics of the drug when administered subcutaneously in healthy participants.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250530123396) on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-31 01:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VANCOUVER, British Columbia-- AbCellera Biologics Inc. (Nasdaq: ABCL) has announced that it has received a No Objection Letter from Health Canada, granting authorization for its Clinical Trial Application for ABCL575. This investigational antibody medicine is being developed to treat moderate-to-severe atopic dermatitis and potentially other inflammatory and autoimmune conditions. ABCL575 is characterized as an Fc-silenced, half-life extended antibody targeting the OX40 ligand. The company plans to initiate a Phase 1 clinical trial in the third quarter of 2025, which will assess the safety and pharmacokinetics of the drug when administered subcutaneously in healthy participants.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250530123396) on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL1p0ljz:1","article_id":"2539271187","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539271187","pubTimestamp":1748624416,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575. VANCOUVER, British Columbia-- AbCellera Biologics Inc.  has announced that it has received a No Objection Letter from Health Canada, granting authorization for its Clinical Trial Application for ABCL575. This investigational antibody medicine is being developed to treat moderate-to-severe atopic dermatitis and potentially other inflammatory and autoimmune conditions. ABCL575 is characterized as an Fc-silenced, half-life extended antibody targeting the OX40 ligand. The company plans to initiate a Phase 1 clinical trial in the third quarter of 2025, which will assess the safety and pharmacokinetics of the drug when administered subcutaneously in healthy participants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","ABCL":"AbCellera Biologics","BK4121":"生命科学工具和服务"},"translate_title":"AbCellera Biologics Inc.获得加拿大卫生部批准进行特应性皮炎治疗ABCL575的1期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":0.9},"content_text":"AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575\n    \n\n        VANCOUVER, British Columbia-- AbCellera Biologics Inc. (Nasdaq: ABCL) has announced that it has received a No Objection Letter from Health Canada, granting authorization for its Clinical Trial Application for ABCL575. This investigational antibody medicine is being developed to treat moderate-to-severe atopic dermatitis and potentially other inflammatory and autoimmune conditions. ABCL575 is characterized as an Fc-silenced, half-life extended antibody targeting the OX40 ligand. The company plans to initiate a Phase 1 clinical trial in the third quarter of 2025, which will assess the safety and pharmacokinetics of the drug when administered subcutaneously in healthy participants.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250530123396) on May 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}